Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc.

Pharma Revenue Costs: Lantheus vs. Amphastar (2014-2023)

__timestamp	Amphastar Pharmaceuticals, Inc.	Lantheus Holdings, Inc.
Wednesday, January 1, 2014	159205000	176081000
Thursday, January 1, 2015	174172000	157939000
Friday, January 1, 2016	150976000	164073000
Sunday, January 1, 2017	149380000	169243000
Monday, January 1, 2018	187681000	168489000
Tuesday, January 1, 2019	190434000	172526000
Wednesday, January 1, 2020	206506000	200649000
Friday, January 1, 2021	238029000	237513000
Saturday, January 1, 2022	250127000	353358000
Sunday, January 1, 2023	293274000	586886000

Unveiling the hidden dimensions of data

Analyzing Cost of Revenue Trends in the Pharmaceutical Industry

In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. This analysis focuses on the cost of revenue trends for Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Lantheus Holdings saw a staggering 233% increase in its cost of revenue, peaking at $586.9 million in 2023. In contrast, Amphastar Pharmaceuticals experienced a more modest 84% rise, reaching $293.3 million in the same year.

Key Insights

Lantheus Holdings, Inc.: The company's cost of revenue surged significantly, particularly from 2021 to 2023, indicating potential strategic investments or increased production costs.
Amphastar Pharmaceuticals, Inc.: While growth was steady, the cost of revenue remained relatively stable until a notable uptick in 2023.

These trends highlight the differing financial strategies and market responses of these two industry players.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Analyzing Cost of Revenue: Johnson & Johnson and Amphastar Pharmaceuticals, Inc.

Cost of Revenue Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.

Cost of Revenue Trends: Incyte Corporation vs Lantheus Holdings, Inc.

Cost Insights: Breaking Down Bio-Techne Corporation and Amphastar Pharmaceuticals, Inc.'s Expenses

Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Lantheus Holdings, Inc.

Lantheus Holdings, Inc. vs Perrigo Company plc: Efficiency in Cost of Revenue Explored

Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses

Lantheus Holdings, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored

Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.

Cost Insights: Breaking Down Xenon Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses

MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored

Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Evotec SE